Tag - NAGE

Feature

Niagen Bioscience innovating NAD+-based therapies from healthy aging to pediatric orphan diseases

Niagen Bioscience (NASDAQ: NAGE) is pioneering the research and development of nicotinamide adenine dinucleotide (NAD+)—a vital coenzyme essential to cellular metabolism, energy production, and DNA repair that declines...

April 28, 2026

Developments

Niagen increases share repurchase program to $20 million

Niagen Bioscience (NASDAQ: NAGE) has announced that its board of directors has authorized an increase to the company’s previously disclosed share repurchase program, raising the total authorization from $10 million to...

March 19, 2026

Tag - NAGE

Niagen Bioscience innovating NAD+-based therapies from healthy aging to pediatric orphan diseases

Niagen increases share repurchase program to $20 million

Subscribe